● Recruiting

A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE

Condition: Sjögren's Syndrome · Sponsor: Lubris Bio Pty Ltd

PhasePhase 2

Planned participants80

Who can joinAll sexes, 18 Years to 80 Years

Healthy volunteersNo

About this study

rhPRG4-Sjögren's-002 is a prospective multi-center study conducted in Australia to evaluate the safety and efficacy of topically-applied rhPRG4 in subjects with Sjögren's related Dry Eye Disease.

This description comes directly from the study's public registry record.

Talk to the study team

Edward CEO · 6193394016 · ertruitt@lubris.net

Always discuss trial participation with your own doctor first.

Locations (6)

Sydney Eye Hospital	Sydney, New South Wales, Australia	Not Yet Recruiting
Univ of New South Wales	Sydney, New South Wales, Australia	Recruiting
OTA	Brisbane, Queensland, Australia	Recruiting
Queensland University of Technology	Brisbane, Queensland, Australia	Recruiting
University of the Sunshine Coast	Maroochydore, Queensland, Australia	Recruiting
University of Melbourne	Melbourne, Victoria, Australia	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07118241